Dabigatran-d3

Dabigatran-d3 is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM) . Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM) [1][2].

Product Specifications

CAS Number

[1246817-44-6]

Product Name Alternative

BIBR 953-d3; BIBR 953ZW-d3

UNSPSC

12352005

Hazard Statement

H225, H302+H312+H332, H319

Target

Thrombin

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Cardiovascular Disease

Purity

99.53

Solubility

DMSO : 10 mg/mL (ultrasonic; warming; adjust pH to 3 with 1 M HCL)

Smiles

OC(CCN(C1=CC=CC=N1)C(C2=CC=C(C(N=C3CNC4=CC=C(C=C4)C(N)=N)=C2)N3C([2H])([2H])[2H])=O)=O

Molecular Formula

C25H22D3N7O3

Molecular Weight

474.53

Precautions

H225, H302+H312+H332, H319

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Wienen W, Stassen JM, Priepke H, In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally activeprodrug, dabigatran etexilate. Thromb Haemost. 2007 Jul;98 (1) :155-62.|[3]Hauel NH, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002 Apr 25;45 (9) :1757-66.|[4]Wienen W, et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost. 2007 Aug;98 (2) :333-8.